Bausch Health Companies Inc. (BHC) Stock Forecast & Analysis

Real-time stock price, financial statements, consensus target price, insider trading, and technical analysis for Bausch Health Companies Inc. (BHC:NYSE), powered by AI.

Current Price
$5.06
P/E Ratio
12.0
Market Cap
1.9B
Sector
Healthcare
What is the Bausch Health Companies Inc. stock price forecast?

Bausch Health Companies Inc. is currently trading at $5.06. View real-time AI analysis on Alpha Lenz.

What is Bausch Health Companies Inc. insider trading activity?

View the latest insider trading data for Bausch Health Companies Inc. on Alpha Lenz.

What is Bausch Health Companies Inc.'s P/E ratio?

Bausch Health Companies Inc.'s P/E ratio is 12.0.

Bausch Health Companies Inc.

NYSE · BHC
$5.06-0.10(-1.94%)Pre-marketNYSE regular session 09:30–16:00 ET
Ask about Bausch Health Companies Inc.'s future dividend policy...
Alpha Chat Insight

Bausch Health Companies Inc. trades at a P/E of 12.0 (undervalued) with modest ROE of -17.1%. Operating margin of 21.3% indicates strong profitability.

Ask for details

Company Overview

Bausch Health Companies Inc. is a diversified healthcare company focused on developing, manufacturing, and marketing branded and generic pharmaceuticals, over-the-counter products, and medical devices. Its portfolio spans gastroenterology, neurology, dermatology, and eye health, with a notable legacy from the acquisition of Bausch + Lomb that established a strong footprint in vision care and ophthalmic pharmaceuticals. Operating within the specialty and generic drug segment, the company emphasizes treatments for chronic conditions and niche therapeutic areas where physician-led adoption and patient adherence are critical. Bausch Health serves patients, healthcare professionals, and institutional buyers across global markets through a mix of prescription brands, generics, and consumer health offerings. The firm’s scale—supported by a large employee base—enables integrated R&D, manufacturing, and distribution, positioning it as a meaningful player in cost-sensitive and specialty therapeutics. Financially, it exhibits characteristics of a value-oriented healthcare issuer, reflecting low price-to-sales and active capital allocation underpinned by ongoing operating profitability metrics.

CEOMr. Thomas J. Appio
SectorHealthcare
IndustryDrug Manufacturers - Specialty & Generic
Employees20,700

Company Statistics

FY 2025

Profile

$1.89BMarket Cap
$10.27BRevenue
0.00Shares Out
20,700Employees

Margins

70.65%Gross
33.52%EBITDA
21.28%Operating
3.57%Pre-Tax
1.17%Net

Valuation

12.05P/E
-3.41P/B
0.18EV/Sales
6.50EV/EBITDA
1.90P/FCF

Growth (CAGR)

8.11%Rev 3Yr
5.04%Rev 5Yr
16.27%Op Inc 3Yr
11.25%Op Inc 5Yr
N/ANet Inc 3Yr
N/ANet Inc 5Yr

Returns

0.45%ROA
-17.13%ROE
7.45%ROIC

Financial Health

$1.31BCash & Cash Equivalents
$24.68BNet Debt
6893.63%Debt/Equity
N/AInterest Cov

Frequently Asked Questions

Bausch Health Companies Inc. (ticker: BHC) is a company listed on NYSE in the Healthcare sector (Drug Manufacturers - Specialty & Generic). It has approximately 20,700 employees. Market cap is $1.9B.

The current price is $5.06 with a P/E ratio of 12.05x and P/B of -3.41x.

ROE is -17.13% and operating margin is 21.28%. Annual revenue is $10.3B.

Alpha Lenz
Singapore
Treasurer Pte Ltd | License: 202346277E
9 Straits View Marina One West Tower #05-07 Singapore 018937
contact@treasurer.co.kr
©2026 Treasurer Pte Ltd. All rights reserved.
Bausch Health Companies Inc. (BHC) Stock Forecast 2026 $5.06 — Price, Financials & Analyst Targets | Alpha Lenz